MIMRELSA

Serial Number 97696650
732

Registration Progress

Application Filed
Nov 29, 2022
Under Examination
Oct 24, 2023
Approved for Publication
Aug 29, 2023
Published for Opposition
Aug 29, 2023
Registered

Attorney Assistance

Statement of Use Due - Extension 3 Granted
Due: Oct 24, 2025 103 days

Trademark Image

MIMRELSA

Basic Information

Serial Number
97696650
Filing Date
November 29, 2022
Published for Opposition
August 29, 2023
Drawing Code
4

Status Summary

Current Status
Active
Status Code
732
Status Date
Apr 15, 2025
Application
Pending
Classes
005 042 044

Rights Holder

Protagonist Therapeutics, Inc.

03
Address
Suite 140
7707 Gateway Boulevard
Newark, CA 94560-1160

Ownership History

Protagonist Therapeutics, Inc.

Original Applicant
03
Newark, CA

Protagonist Therapeutics, Inc.

Owner at Publication
03
Newark, CA

Legal Representation

Attorney
Frances M. Jagla

USPTO Deadlines

Next Deadline
103 days remaining
Statement of Use Due - Extension 3 Granted
Due Date
October 24, 2025
Extension Available
Until October 24, 2024

Application History

29 events
Date Code Type Description
Apr 16, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 15, 2025 EX3G S SOU EXTENSION 3 GRANTED
Apr 15, 2025 EXT3 S SOU EXTENSION 3 FILED
Apr 15, 2025 EEXT I SOU TEAS EXTENSION RECEIVED
Oct 11, 2024 EX2G S SOU EXTENSION 2 GRANTED
Oct 11, 2024 EXT2 S SOU EXTENSION 2 FILED
Oct 11, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 11, 2024 EEXT I SOU TEAS EXTENSION RECEIVED
Mar 13, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 12, 2024 EX1G S SOU EXTENSION 1 GRANTED
Mar 12, 2024 EEXT I SOU TEAS EXTENSION RECEIVED
Mar 12, 2024 EXT1 S SOU EXTENSION 1 FILED
Oct 24, 2023 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Aug 29, 2023 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 29, 2023 PUBO A PUBLISHED FOR OPPOSITION
Aug 9, 2023 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 20, 2023 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 18, 2023 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 17, 2023 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 17, 2023 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 26, 2023 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 26, 2023 GNRT F NON-FINAL ACTION E-MAILED
Jun 26, 2023 CNRT R NON-FINAL ACTION WRITTEN
Jun 25, 2023 DOCK D ASSIGNED TO EXAMINER
Jan 5, 2023 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jan 5, 2023 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jan 5, 2023 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Dec 22, 2022 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 2, 2022 NWAP I NEW APPLICATION ENTERED

Detailed Classifications

Class 005
Pharmaceuticals for use in the treatment of cancer and blood diseases and disorders
Class 042
Medical research and medical research information services in the fields of pharmaceuticals, oncology, and blood diseases and disorders
Class 044
Medical information services in the fields of pharmaceuticals, oncology, and blood diseases and disorders

Classification

International Classes
005 042 044

USPTO Documents

Click to view cached USPTO documents for this trademark

Only administrators can request new documents from USPTO